These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16315127)

  • 1. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD; Ewald N
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM; Stein JM
    Br J Cancer; 2008 Oct; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
    Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Screening for colorectal cancer: what is the most effective strategy?].
    Merzenich H; Giersiepen K; Kieschke J; Zeeb H
    Gesundheitswesen; 2005 Nov; 67(11):803-8. PubMed ID: 16308813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in colorectal cancer screening.
    Pox CP
    Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.